B7-2/CD86
B7-2 (CD86) is the second B7-family co-stimulatory ligand, a type I transmembrane protein constitutively present at low levels on resting B cells, monocytes and dendritic cells and rapidly upregulated (within hours) upon activation, preceding the slower CD80 induction. CD86 binds CD28 to deliver primary co-stimulatory signals for naive T-cell priming, and CTLA-4 with intermediate avidity; the kinetic distinction CD86 (fast, transient, lower CTLA-4 affinity) versus CD80 (slow, sustained, higher CTLA-4 affinity) tunes the balance between initial T-cell activation and later inhibitory feedback. CD86 also engages PD-L1 in cis and binds the inhibitory receptor BTLA indirectly via HVEM complexes in some contexts. In autoimmunity, persistent CD86 expression on B cells and APCs propagates chronic T-cell activation in lupus, rheumatoid arthritis and type 1 diabetes; abatacept (CTLA4-Ig) preferentially intercepts CD86 to blunt co-stimulation. CD86 also marks follicular lymphoma cells and supports germinal-center T-cell help.
-
B7-2/CD86 Protéines Recombinantes (13)
- Species:
- Source:
- Species:
- Source:
- Species:
- Source:
- Species:
- Source:
- Species:
- Source:
- Species:
- Source:
- Species:
- Source:
- Species:
- Source:
- Species:
- Source:
- Species:
- Source:
- Species:
- Source:
- Species:
- Source:
- Species:
- Source:
- 1
Recombinant Protein Expression Service
- Codon Optimization
- Gene Synthesis
- Construction of Expression Vector
- Strain Screening
- Protein Expression
- Purification & QC
- Protein Delivery
- 1
- Formule: Human
- Masse moléculaire: Sf9 insect cells
The EpCAM/TROP1 protein serves as an important homogeneous interacting molecule that promotes direct contact between intestinal epithelial cells (IEC) and intraepithelial lymphocytes (IEL) in the mucosal epithelium. This feature helps establish an immune barrier against mucosal infections. EpCAM/TROP1 Protein, Human (His-SUMO) is the recombinant human-derived EpCAM/TROP1 protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag.
